Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group

[1]  R. Stupp,et al.  Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients , 2004, Clinical Cancer Research.

[2]  R. Parker,et al.  A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  G. Rustin,et al.  Effect of temozolomide on central nervous system relapse in patients with advanced melanoma , 2002, Melanoma research.

[4]  J. Melo,et al.  Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[5]  M. Atkins,et al.  A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  G. Weiss,et al.  Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Hersey,et al.  The chemoresistance of human malignant melanoma: an update. , 1999, Melanoma research.

[8]  M. Roddie,et al.  Phase I trial of temozolomide using an extended continuous oral schedule. , 1998, Cancer research.

[9]  A. Buzaid,et al.  Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Buckner,et al.  Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  D. Kondziolka,et al.  Stereotactic radiosurgery for cerebral metastatic melanoma. , 1993, Journal of neurosurgery.

[12]  E. Newlands,et al.  Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. , 1993, British Journal of Cancer.

[13]  E. Newlands,et al.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). , 1992, British Journal of Cancer.

[14]  H. Thames,et al.  Clinical radiobiology of malignant melanoma. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  M. Mitchell.  Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Tisdale.  Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. , 1987, Biochemical pharmacology.

[17]  J. Cooper,et al.  Brain metastases from malignant melanoma: conventional vs. high-dose-per-fraction radiotherapy. , 1986, International journal of radiation oncology, biology, physics.

[18]  C. Karakousis,et al.  Malignant melanoma brain metastases. Review of roswell park memorial institute experience , 1984, Cancer.

[19]  G. Hutchins,et al.  Patterned distribution of metastases from malignant melanoma in humans. , 1983, Cancer research.

[20]  J. Cooper,et al.  Radiotherapy of intracerebral metastatic malignant melanoma. , 1980, Radiology.

[21]  R. Gelber,et al.  Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma. Radiation therapy oncology group brain metastases study I and II , 1980, Cancer.

[22]  V. Vaitkevicius,et al.  Malignant melanoma and central nervous system metastases. Incidence, diagnosis, treatment and survival , 1978, Cancer.

[23]  D. Crowther,et al.  In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue , 2004, Cancer Chemotherapy and Pharmacology.

[24]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Liotta,et al.  Biology of melanoma invasion and metastasis. , 1987, Pigment cell research.

[26]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.